首页> 外文期刊>American Journal of Surgical Pathology >Pituitary tumors and hyperplasia in multiple endocrine neoplasia type 1 syndrome (MEN1): a case-control study in a series of 77 patients versus 2509 non-MEN1 patients.
【24h】

Pituitary tumors and hyperplasia in multiple endocrine neoplasia type 1 syndrome (MEN1): a case-control study in a series of 77 patients versus 2509 non-MEN1 patients.

机译:多发性内分泌肿瘤1型综合征(MEN1)的垂体瘤和增生:病例对照研究,针对77例患者和2509例非MEN1患者。

获取原文
获取原文并翻译 | 示例
           

摘要

Patients affected by the multiple endocrine neoplasia type I syndrome (MEN1) display a high incidence of pituitary adenomas, though it is still unknown whether these pituitary tumors have specific pathologic features that would distinguish them from sporadic pituitary adenomas. Pituitary tissue specimens of 77 MEN1 patients from the GTE (Groupe d'etude des Tumeurs Endocrines) register were compared with unselected 2509 non-MEN1 sporadic pituitary tumors and also to a control subgroup of 296 cases, where 1 MEN1 tumor was matched with 4 sporadic tumors of the same hormonal immunoprofile. Sex, age, size, and invasiveness of tumors, and menin gene mutations were documented. Histologic analysis took into account 33 items, including immunocytochemical data, the proliferative marker Ki-67, and an examination of the juxtatumoral pituitary. MEN1 tumors were significantly larger and more often invasive by histology. MEN1 patients with large pituitary tumors (grade IV) were younger than non-MEN1 patients. MEN1 tumors had no other characteristic histologic features and no predominance of any one hormone producing subtype. However, plurihormonal adenomas versus monohormonal and nonimmunoreactive adenomas were more frequent in MEN1 tumors (39%) than in the control non-MEN1 group (P = 0.001). Especially, the growth hormone and prolactin plurihormonality with unusual association with follicle-stimulating hormone, luteinizing hormone, or adrenocorticotropic hormone was more frequent in MEN1 tumors. In addition, multiple adenomas were significantly more frequent (4% vs. 0.1%; P < 0.0001), especially prolactin-adrenocorticotropic hormone. Somatotroph hyperplasia, with or without a microadenoma was found in only 3 MEN1 patients, with growth hormone-releasing hormone hypersecretion by a pancreatic tumor in 2 of them. All types of mutation were observed, including frameshifts, nonsenses, missenses, and 1 case of germline MEN1 encompassing large deletion, strongly suggesting the absence of any phenotype-genotype correlation.
机译:尽管目前尚不清楚这些垂体肿瘤是否具有可将其与散发性垂体腺瘤区分开的特定病理特征,但仍受I型多发性内分泌瘤形成综合征(MEN1)影响的患者表现出很高的发病率。将来自GTE(Groupe d'etude des Tumeurs内分泌科)登记册的MEN1患者的77例垂体组织标本与未选择的2509例非MEN1散发性垂体瘤进行比较,并与296例对照组进行比较,其中1例MEN1肿瘤与4例散发激素免疫特性相同的肿瘤。记录了肿瘤的性别,年龄,大小和侵袭性以及menin基因突变。组织学分析考虑了33个项目,包括免疫细胞化学数据,增殖标记Ki-67以及垂体垂体检查。 MEN1肿瘤明显更大,并且从组织学上看更容易浸润。患有大垂体瘤的MEN1患者(IV级)比非MEN1患者年轻。 MEN1肿瘤没有其他特征性组织学特征,也没有任何一种激素产生亚型的优势。但是,MEN1肿瘤中的胸膜激素性腺瘤与单激素性和非免疫反应性腺瘤相比(39%)的发生率要高于对照组非MEN1组(P = 0.001)。特别是在MEN1肿瘤中,生长激素和催乳激素的多激素性与促卵泡激素,促黄体生成激素或促肾上腺皮质激素异常相关。此外,多发性腺瘤的发生率明显更高(4%vs. 0.1%; P <0.0001),尤其是催乳激素-促肾上腺皮质激素。仅3例MEN1患者中发现伴有或不伴有微腺瘤的体营养型增生,其中2例胰腺肿瘤导致生长激素释放激素分泌过多。观察到所有类型的突变,包括移码,废话,错义和1例种系MEN1包含大缺失,强烈暗示没有任何表型与基因型相关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号